We are live on ! Find out more
PHAT icon

Phathom Pharmaceuticals
PHAT

79 hedge funds and large institutions have $843M invested in Phathom Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 34 increasing their positions, 14 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

143% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 14

1.14% more ownership

Funds ownership: 78.4% → 79.54% (+1.1%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

6% less funds holding

Funds holding: 84 → 79 (-5)

8% less capital invested

Capital invested by funds: $919M → $843M (-$75.8M)

29% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 17

Holders
79
Holders Change
-5
Holders Change %
-5.95%
% of All Funds
1.38%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
12
Increased
34
Reduced
14
Closed
17
Calls
$339K
Puts
–
Net Calls
+$339K
Net Calls Change
+$342K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$12.3M
2
RCAMU
Rothschild & Co Asset Management US
Connecticut
+$6.14M
3
State Street
State Street
Massachusetts
+$4.41M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$4.13M
5
WCM Investment Management
WCM Investment Management
California
+$3.72M

Top Sellers

Rank Fund Capital Flow
1
GGHC
Gilder Gagnon Howe & Co
New York
-$9.74M
2
CCM
CAAS Capital Management
New York
-$7.92M
3
JP Morgan Chase
JP Morgan Chase
New York
-$6.52M
4
Marshall Wace
Marshall Wace
United Kingdom
-$3.01M
5
WP
Woodline Partners
California
-$1.56M
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
26
Adage Capital Partners
Massachusetts
$2.76M – – –
Citadel Advisors
27
Citadel Advisors
Florida
$2.72M +$2.57M +71,833 +841%
Bank of America
28
Bank of America
North Carolina
$2.15M -$52.3K -1,460 -2%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$1.72M +$344K +9,597 +23%
PVI
30
Pura Vida Investments
New York
$1.53M -$665K -18,561 -29%
Two Sigma Investments
31
Two Sigma Investments
New York
$1.35M -$525K -14,671 -27%
SEI Investments
32
SEI Investments
Pennsylvania
$1.33M +$1.41M +39,428 New
MWNA
33
Marshall Wace North America
New York
$1.17M -$111K -3,094 -8%
SRA
34
Summit Rock Advisors
New York
$1.15M – – –
Swiss National Bank
35
Swiss National Bank
Switzerland
$1.05M +$516K +14,400 +87%
Marshall Wace
36
Marshall Wace
United Kingdom
$1.01M -$3.01M -84,154 -74%
California State Teachers Retirement System (CalSTRS)
37
California State Teachers Retirement System (CalSTRS)
California
$946K +$375K +10,475 +60%
Morgan Stanley
38
Morgan Stanley
New York
$896K +$947K +26,433 +44,802%
Two Sigma Advisers
39
Two Sigma Advisers
New York
$863K -$211K -5,900 -19%
CIP
40
Chartwell Investment Partners
Pennsylvania
$765K +$809K +22,589 New
New York State Common Retirement Fund
41
New York State Common Retirement Fund
New York
$592K +$279K +7,795 +80%
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$556K +$181K +5,048 +44%
Cambridge Investment Research Advisors
43
Cambridge Investment Research Advisors
Iowa
$552K – – –
State of Wisconsin Investment Board
44
State of Wisconsin Investment Board
Wisconsin
$504K – – –
BFM
45
Boothbay Fund Management
New York
$504K +$82.3K +2,298 +18%
PP
46
PDT Partners
New York
$504K +$534K +14,900 New
EGM
47
Engineers Gate Manager
New York
$484K +$181K +5,054 +55%
OAM
48
Occidental Asset Management
California
$436K – – –
Russell Investments Group
49
Russell Investments Group
United Kingdom
$428K +$454K +12,676 New
Deutsche Bank
50
Deutsche Bank
Germany
$425K +$184K +5,144 +69%
1
2
3 4

PHAT Hedge Fund Activity: Q2 2021 in Review

79 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q2 2021, worth a combined $843M — down 8.2% from $919M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of PHAT and 12 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 34 added.

The largest buyer was BlackRock, adding an estimated $12.3M. The largest seller was Gilder Gagnon Howe & Co, cutting an estimated $9.74M.

  • 79 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q2 2021, down from 84 in Q1 2021.
  • Funds reported $843M of Phathom Pharmaceuticals stock for Q2 2021, down 8.2% quarter-over-quarter.
  • 12 funds opened new Phathom Pharmaceuticals positions in Q2 2021 and 17 closed out, a net change of -5 holders.
  • The largest Phathom Pharmaceuticals buyer in Q2 2021 was BlackRock, an estimated $12.3M added.
  • The largest Phathom Pharmaceuticals seller in Q2 2021 was Gilder Gagnon Howe & Co, an estimated $9.74M sold.

Based on aggregated 13F filings for Q2 2021.